# A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Source: https://onco.cc/trials/nct06010303/  
OnCo record `nct06010303` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Alcestobart run by BeiGene, completed.

## Summary

A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma is a phase 2 interventional study registered as NCT06010303 by BeiGene, with 118 participants enrolled, started 2023-11-08. Conditions recorded: Esophageal Cancer, Esophageal Squamous Cell Carcinoma and Esophageal Squamous Cell Carcinoma by AJCC V8 Stage. Interventions recorded: LBL-007, Tislelizumab and Chemotherapy Doublet.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06010303
- Phase: 2
- Setting: A Phase 2, Randomized, Active-Controlled, Open-Label Study to Evaluate the Efficacy and Safety of LBL-007 in Combination With Tislelizumab Plus Chemotherapy as First-Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
- Sponsor: BeiGene
- Enrolled: 118

## Sources

- ClinicalTrials.gov NCT06010303: https://clinicaltrials.gov/study/NCT06010303

## Connected records

- cancers: [Oesophageal cancer](https://onco.cc/cancers/esophageal/), [Oesophageal squamous cell carcinoma](https://onco.cc/cancers/oesophageal-squamous-cell-carcinoma/)
- drugs: [Alcestobart](https://onco.cc/drugs/alcestobart/)
- companies: [Nanjing Leads Biolabs](https://onco.cc/companies/nanjing-leads-biolabs/)

---
JSON: https://onco.cc/api/v1/entities/nct06010303.json